the body with axillary and inguinal freckles. So, a diagnosis of type 1 neurofibromatosis (NF-1) was made. Examination findings of respiratory tract were suggestive of left sided pleural effusion. On abdominal examination a tender, firm to hard (10cm x 8cm) epigastric swelling was noted with fixity to underlying structure and overlying skin. Cardiovascular and neurological examination were within normal limit. Contrast enhanced CT scan of abdomen and thorax showed a large (11cm17cm) complex heterogenous upper abdominal mass with upward extension towards left hemithorax along the paracardiac region in the left lung up to the horizontal level of main pulmonary artery ( Figure 1 ). diaphragm and parietal wall with extension to the abdomen. So, resection of the tumour could not be done. Patient received chemotherapy with doxorubicin, cyclophosphamide and vincristin for 2 cycles after which he died subsequently. A sarcoma is defined as MPNST if at least two of the following criteria are met with. (1) It arises from a peripheral nerve, (2) It arises from a pre-existing benign nerve sheath tumour (neurofibroma), (3) It demonstrates Schwann cell differentiation on histological examination. The incidence of MPNST in general population is 0.001%. Its incidence in patients with NF1 is 4.6%. 2 Up to 50% of MPNST occurring in patients with NF1 arises from a pre-existing neurofibroma. 3 Overall NF1 patients have a 4% lifetime risk of ultimately developing a MPNST. 4 MPNST in patients of NF-1 generally occurs in adulthood, median age being 30 years only. 5 MPNSTs most commonly occur in the deep soft tissues, usually close to a nerve trunk. The most common sites are the sciatic nerve, brachial plexus, and sacral plexus. It usually presents as an enlarging palpable mass. Pain is a variable complaint. Rapid enlargement occurs more often in patients of NF1. Neurofibromas typically have low attenuation on CT, which may be related to the fat content of myelin from Schwann cells, the high water content of myxoid tissue, entrapment of fat, and cystic areas of hemorrhage and necrosis. 6 MPNST arising from a peripheral nerve may result in variable clinical patterns including radicular pain, paresthesia and motor weakness of muscles. Haematogenous metastasis from MPNST occurs most commonly in lungs. 7 S-100 is traditionally regarded as the best marker for malignant peripheral nerve sheath tumour; however, it is positive in only about one third to half the tumors. 8 The negative reaction may be caused by not only tumour cell anaplasia but also by different constituents other than Schwann cell. All perineural MPNST were S100 protein negative and EMA and/or GLUT1 positive. For the immunohistochemical diagnosis of MPNST, nerve sheath markers other than S100 protein such as CD57 (Leu7), EMA, Glut1, CD34 should also be included in the panel of antibodies. 9 There was also presence of massive left sided pleural effusion with lung mass. (Figure 2 ). Plenty of blood vessels with thrombus within it and areas of necrosis was seen. On immunohistochemistry, the tumour cell was S100 positive, immunonegative to c-kit and CD34. Mib levelling index was 70%. In context of history of NF-1, the above histopathological picture was suggestive of MPNST. CT scan and MRI of brain did not reveal any abnormality. On thoracotomy, the mass was fixed to the The reported five year survival for patients with MPNST without NF1 is as high as 50%.It drops down to as low as 10% in MPNST patients with NF1. 7 Treatment consists of complete and wide surgical resection. 10 Adjuvant irradiation seems to improve local control of the disease. Use of chemotherapy is only employed in high grade disease in which metastatic disease is likely. Chemotherapy can be administered in preoperative or postoperative settings. The prognosis depends on tumour size, surgical excision margin, and histological presence of necrosis and history of prior irradiation. 8 . MPNST itself is a rare disease. Moreover MPNST being associated with NF-1 was more uncommon. Initial Presentation having abdominal mass with extension into the lung made the case more atypical. Patient did not respond to chemotherapy as he fell into bad prognosis group due to presence of large size tumour, failure of surgical resection and presence of necrosis in the histopathological specimen.
Discussion:
NF-1 is an autosomal dominant genetic disorder with a prevalence of approximately 1 in 4,000 births and no racial predilection. 1 NF-1 is diagnosed by any two of the six criteria (1) Multiple cafe-au-lait macules larger than 1.5cm in diameter and more than six in number. (2) Axillary or inguinal freckles,Two or more neurofibromas of any type or one plexiform neurofibroma, (3) Sphenoid wing dysplasia or congenital bowing of long bone cortex with or without pseudoarthrosis, (4) Bilateral optic nerve glioma, two or more Lisch nodules
